A critical medicine is a medicinal product for which insufficient supply results in serious harm or risk of serious harm to patients. There can be risks and weaknesses in the supply chain of certain critical medicines, which may compromise the continuous supply of critical medicines to patients in the Union, in particular in crisis situations, such as a pandemic. Such risks and weaknesses potentially warrant targeted public intervention, including funding, in particular in manufacturing capacities for critical medicines, their active substances and other key inputs. When a market failure regarding the security of supply of a specific critical medicine is identified at Union level or at the level of one or several Member States by means of a vulnerability assessment, all or some of the Member States concerned should be able to choose to entrust specific public service obligations to operators to enhance the security of supply for such critical medicines. Compensation for critical medicines SGEI below the general compensation threshold should therefore be exempted from the notification requirement pursuant to Article 108(3) of the Treaty.
Recital 27, Decision_act (EU) 2025/2630
In forcesince 16 Dec 2025